

Table S1. Associations between ERAP1, TNFRSF1B, TNFRSF1A, FCGR2A genotypes and clinical parameters.

		N	Min	Q1	Median	Q3	Max	IQR	P ^a	P ^b
ERAP1 rs2287987										
CRP at baseline [mg/l]	AA	69	0.42	4.29	10.8	26.8	99.8	22.5	0.032	AA vs AG + GG 0.012
	AG	33	0.35	1.19	2.77	19.2	68.8	18.0		AA + AG vs GG 0.916
	GG	3	3.64	3.64	4.83	37.93	37.9	34.3		AA + GG vs AG 0.009
CRP at 12th week [mg/l]	AA	69	0.13	0.66	1.65	5.66	26.7	5.0	0.020	AA vs AG 0.010
	AG	33	0.1	0.33	0.78	2.075	108.3	1.75		AG vs GG 0.319
	GG	2	5.75	5.75	10.2	14.7	14.7	8.94		AA vs GG 0.735
CRP at 24th week [mg/l]	AA	68	0.08	0.578	1.83	5.73	37.6	5.15	0.015	AA vs AG + GG 0.043
	AG	32	0.13	0.335	0.635	2.77	27.5	2.43		AA + AG vs GG 0.134
	GG	3	2.77	2.77	4.6	10.2	10.2	7.47		AA + GG vs AG 0.009
TNFRSF1B rs1061622										
VAS at baseline [mm]	TT	58	45	70	80	85	100	15	0.003	TT vs TG + GG 0.653
	TG	34	48	70	79	82.3	93	12.3		TT + TG vs GG 0.001*
	GG	8	80	84.8	93	95	100	10.3		TT + GG vs TG 0.144
BASDAI at baseline	TT	64	4.05	5.9	7.3	8.2	9.8	2.3	0.015	TT vs TG 0.451
	TG	34	3.95	5.84	7.05	7.93	9.2	2.09		TG vs GG 0.001*
	GG	8	6.35	7.78	8.6	9.3	10	1.53		TT vs GG 0.002*
TNFRSF1A rs767455										
CRP at baseline [mg/l]	TT	34	0.68	4.25	18.2	40.1	99.8	35.9	0.017	TT vs TC + CC 0.009
	TC	46	0.35	1.69	5.29	14.8	59.7	13.1		TT + TC vs CC 0.991
	CC	25	0.76	2.79	7.85	18.7	51.9	15.9		TT + CC vs TC 0.014
ESR at baseline [mm/h]	TT	33	1	13	32	50	93	37	0.027	TT vs TC 0.006*
	TC	46	2	4.75	15.5	32.3	70	27.5		TC vs CC 0.231
	CC	25	2	8	22	38.5	64	30.5		TT vs CC 0.120
ESR at 24th week [mm/h]	TT	33	1	13	32	50	93	37	0.027	TT vs TC + CC 0.013
	TC	46	2	4.75	15.5	32.3	70	27.5		TT + TC vs CC 0.991
	CC	25	2	8	22	38.5	64	30.5		TT + CC vs TC 0.020
FCGR2A rs1801274										
ESR at 24th week [mm/h]	AA	38	1	3	9.5	16.8	57	13.8	0.045	AA vs AG + GG 0.064
	AG	50	1	3	5	12.8	46	9.75		AA + AG vs GG 0.030
										AA + GG vs AG 0.829

	<i>AA</i>	<i>AG</i>	<i>GG</i>	<i>AA vs AG</i>	0.230
			<i>AG vs GG</i>	0.103	
			<i>AA vs GG</i>	0.013	

N: number of patients in groups; CRP: C-reactive protein; ESR: Erythrocyte Sedimentation Rate; VAS: Visual Analogue Scale; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; Q1: lower quartile; Q3: upper quartile; IQR: interquartile range

^aKruskal-Wallis test

^bMann-Whitney test, p < 0.008 was considered significant (according to Bonferroni correction) and marked by asterisk (*)